

Combination of Polymyxin B and Rifampicin is Synergistic Against Intracellular P. aeruginosa

FRIDAY - AAR-810 Session P443-AAR08

Abstract

Background:

P. aeruginosa (Pa), an opportunistic pathogen, is a leading agent of hospital-acquired infections and chronic infections in patients with cystic fibrosis, causing morbidity and mortality [1, 2]. Those infections are hard to eradicate as Pa is intrinsically resistant to many common antibiotics, largely due to low permeability of outer membrane [3], which hampers the entrance of antibiotics. In addition, Pa evades immune system and benefits from diminished local concentrations of antibiotics by forming biofilms [4], and hiding inside phagocytic [5] and epithelial cells [6]. Polymyxins are synergistic with many drugs by improving their penetration inside Gram-negative bacteria. Our aim was to examine the effect of polymyxin B in combination with rifampicin, a disused antibiotic for which Pa resistance is low, against intracellular forms of infection.

Methods:

ATCC27853 and PAO1 were used. Extracellular activity of the combination was measured by cfu counting in cationadjusted MHB. Intracellular activity was evaluated using an established model of infected THP-1 cells [5]. Synergy was assessed assuming dose additivity (Loewe's model) and using Hill-Langmuir equation for concentration-response

Results:

Unexpectedly, rifampicin alone had higher efficacy on intracellular bacteria compared to those growing in broth. A strong synergy was observed when combined with polymyxin B against both strains intracellularly while zero interaction was observed in broth. In an attempt to explain these results, extracellular activity was also measured in broth acidified to pH 5.5, plausibly mimicking the pH that Pa encounters in vacuoles. In these conditions, the strong synergistic interaction seen during intracellular infection was reproduced.

Conclusion

The combination of rifampicin and polymyxin B is highly synergistic against intracellular Pa, possibly thanks to the acidic pH of the vacuoles hosting bacteria in infected cells.

References

- [1] Lyczak *et al*. 2000 Microbes Infect 2:1051-60.
- [2] Rowe et al. 2005 N Engl J Med 352:1992-2001.
- [3] Hancock 1998 Clin Infect Dis 27:S93-9
- [4] Høiby et al. 2010 Int J Antimicrob Agents 35:322-32.
- [5] Buyck *et al.* 2013 AAC 57:2310-18.
- [6] Sana *et al*. 2015 MBio 6:e00712

Acknowledgments and Funding

VV and ED were supported by the 2nd call of the European Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). GW is supported by the China Scholarship Council. FVB is Senior Research Associate of the F.R.S.-FNRS. PMT is emeritus professor and was unpaid. This work was supported by the 2nd call of JPIAMR.

Background and Aims

P. aeruginosa (Pa) causes recalcitrant infections [1, 2] that are hard-to-treat due to pathogen's low permeability to antibiotics [3] and its hiding in biofilms [4] and inside host cells [5-6]. Polymyxins work by disrupting bacterial membranes of Gramnegative bacteria and, in doing so, are the antidote of permeability issues encountered by many anti-Gram negative antibiotics.

Our laboratory has developed pharmacodynamic models to assess the extra- and intracellular efficacy and potency of antibiotics in a quantitative manner [5].

Our aim was to examine the potential of polymyxin B (PMB) in combination with rifampicin (RIF), a disused antibiotic for which Pa resistance is low, against intracellular forms of infection.

I. Strains: P. aeruginosa ATCC 257853 and PAO1.

- regression (Hill-Langmuir equation) fixing the slope at 1.
- as described above for intracellular bacteria.
- model)

Key Conclusions and Outlook

- monocytes during intracellular infection.
- molecular foundations of synergy.

Vallo Varik, Emilien Drouot, Gang Wang, Paul M. Tulkens, Françoise Van Bambeke

Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium

Methods

2. MIC determinations: microdilution (CLSI recommendations) with susceptibility assessed according to the EUCAST interpretive criteria (http://www.eucast.org).

. Antibiotic activity against intracellular bacteria: (i) phagocytosis of bacteria by human THP-1 monocytes; (ii) elimination of non-internalized bacteria by exposure to gentamicin; (iii) incubation with a wide range of extracellular concentrations (0.003-100 x MIC) of RIF and PMB for 24 h to obtain full spectrum of concentration-response outcomes.

Intracellular activity evaluated at 24h as the change in CFU (log₁₀ units) from the initial inoculum. Concentration-response results were fitted with four-parameter logistic

4. Antibiotic activity against bacteria in broth: overnight culture of bacteria was diluted to 0.5 x 10⁶ CFU/mL in fresh cation adjusted Mueller-Hinton medium and subjected to wide range of antibiotic concentrations (0.003-100 x MIC) of RIF and PMB for 24 h at 37 °C, 130 rpm in test tubes at a final volume of 2 mL. The activity of antibiotics was evaluated

5. The zero interaction effect of combinatorial drug treatment (mere additivity of the drugs) was predicted from concentration-response curves assuming dose additivity (Loewe's

 \succ Combination of polymyxin B and rifampicin is markedly synergistic, it eradicates two orders of magnitude more intracellular bacteria than expected from the combined effects of monotherapies.

Some of the synergy is possibly potentiated by the acidic environment Pseudomonas aeruginosa encounters in vacuoles where it resides in

We are currently working to explore the generality of this observation on other Gram-negative ESKAPE pathogens and to elucidate the



Certain combinations of polymyxin B and rifampicin are synergistic in acidic conditions. Circles on figures 1-4 stand for change in CFUs after 24h of antibiotic treatment from an initial inoculum of 10⁶ CFU/mL. Red circles stand for the results of rifampicin and yellow for polymyxin monotherapy. From the results of monotherapies, the expected outcome was calculated for the combinations of the two drugs assuming there is no drug-drug interaction (grey surface). The measured experimental outcome of combinations is recorded as black figures. For better visualization: (1) the combination results (black circles) are connected with lines to the zero interaction surface, (2) lines and regions of surface are colored blue for synergies and red for antagonisms.



Results

| 5. Combination of polymyxin B and | 5. Combination | on of p | olymy | xin E | 8 and |
|-----------------------------------|----------------|---------|-------|-------|-------|
|-----------------------------------|----------------|---------|-------|-------|-------|

| Growth conditions | Polymyxin B (mg/L) | Rifampicin (mg/mL) | Measured true effect ^a | Zero interaction ^b | Δc | p-value ^d |
|----------------------------|-----------------------|-----------------------|--------------------------------------|----------------------------------|------|----------------------|
| Intracellular ^e | 0.3 | 4.8 | -1.3 | 0.6 | -1.9 | *** |
| | 1 | 4.8 | -2.5 | 0.3 | -2.8 | *** |
| | 3 | 4.8 | -2.1 | -0.1 | -2 | *** |
| Broth pH 5.5 ^f | 0.075 | 0.024 | -2 | 0.2 | -2.2 | * |
| | 0.075 | 0.24 | -2.4 | 0.1 | -2.5 | * |
| | 0.075 | 8 | -4.1 | -1.2 | -2.9 | * |
| Broth pH 7.4 ^g | 0.3 | 4.8 | 0.3 | 0.2 | 0.1 | NS |
| | 3 | 4.8 | -0.8 | -1.6 | 0.8 | NS |

^a log₁₀ change in CFUs after 24h incubation with antibiotics from starting value (10⁶ CFU/mL) ^b additive effec of Loewe calculated from the effects of monotherapies ^c difference between predicted zero interaction (no synergy/antagonism) and true measured effect ^d p-value for 0-hypothesis that measured effect is not different from zero interaction; *** < 0.001, * < 0.05, NS not significant ^e THP-1 monocytes infected with an average of 1 bacteria/cell after phagocytosis and washing f cation-adjusted Mueller-Hinton broth with 100 mM MES at pH 5.5 ⁹ cation-adjusted Mueller Hinton broth

This poster is available by visiting http://www.facm.ucl.ac.be/posters or by reading this code and selecting the poster

Mailing address:

P.M. Tulkens av. Mounier 73 (B1.73.05) 1200 Brussels, Belgium tulkens@facm.ucl.ac.be +32-2-762-2136



I rifampin results in two orders of magnitude better killing than expected